Subsequent anticancer therapy analysis of the Phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma - van Bömmel, F; Abou-Alfa, G K; Chan, S L; Sangro, B; Lau, G; Kudo, M; Breder, V V; Varela, M; Crysler, O V; Bouattour, M; Dao, T V; Faccio, A; Furuse, J; Kang, Y K; Jeng, L-B; Kelley, R K; Nakamura, H; Schmidt, J; Ali, S; Rimassa, L (Zeitschrift für Gastroenterologie, 2025)